These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Criteria-based DUE aids in selection of preferred agent. Drea EJ Hosp Formul; 1991 Nov; 26 Suppl D():25-7. PubMed ID: 10136562 [TBL] [Abstract][Full Text] [Related]
8. Formulary designation of cimetidine as the primary intravenous histamine H2-receptor antagonist. Berkowitz HS Am J Hosp Pharm; 1992 Jan; 49(1):134-5. PubMed ID: 1349201 [No Abstract] [Full Text] [Related]
9. Experience with a two-tiered therapeutic interchange policy. Rich DS Am J Hosp Pharm; 1989 Sep; 46(9):1792-8. PubMed ID: 2572167 [TBL] [Abstract][Full Text] [Related]
11. Implementing therapeutic interchange of intravenous famotidine for cimetidine and ranitidine. Oh T; Franko TG Am J Hosp Pharm; 1990 Jul; 47(7):1547-51. PubMed ID: 2114789 [TBL] [Abstract][Full Text] [Related]
12. Use of concurrent monitoring and a preprinted note to modify prescribing of i.v. cimetidine and ranitidine in a teaching hospital. Dannenhoffer MA; Slaughter RL; Hunt SN Am J Hosp Pharm; 1989 Aug; 46(8):1570-5. PubMed ID: 2773962 [TBL] [Abstract][Full Text] [Related]
13. Bar-code technology applied to drug-use evaluation. Zarowitz BJ; Petitta A; Mlynarek M; Touchette M; Peters M; Long P; Patel R Am J Hosp Pharm; 1993 May; 50(5):935-9. PubMed ID: 8099468 [TBL] [Abstract][Full Text] [Related]
14. Reducing costs with formulary limitation of H2-receptor antagonists in a community hospital. Coppola P Hosp Pharm; 1991 Feb; 26(2):126-9, 142. PubMed ID: 10136547 [TBL] [Abstract][Full Text] [Related]
15. Use of staff pharmacists to reduce the inappropriate use of parenteral histamine-2 antagonist therapy. Caldwell RD; Davis SK Hosp Pharm; 1987 Dec; 22(12):1205-9. PubMed ID: 10285375 [TBL] [Abstract][Full Text] [Related]
16. Effect of a criteria-based cost-containment program on the selection of oral H2-receptor antagonists. Falbe WJ; Bess DT; Capers CC; Haymond JD; Stahl AA Am J Hosp Pharm; 1992 Mar; 49(3):632-3. PubMed ID: 1598944 [No Abstract] [Full Text] [Related]
17. Achieving rational therapeutics through consensus-based protocols and follow-up. Quintiliani R; Gousse GC; Chow MS Hosp Formul; 1990 Mar; 25(3):283-4, 289-94. PubMed ID: 10103836 [TBL] [Abstract][Full Text] [Related]
18. A pharmacoeconomic analysis of IV H2-receptor antagonist use in 40 hospitals. Segal R; Oh T; Ben-Joseph R; Russell WL Hosp Formul; 1994 May; 29(5):379-82, 388-91. PubMed ID: 10136601 [TBL] [Abstract][Full Text] [Related]
19. Savings achieved through cephalosporin surveillance. Katz E; Schlamowitz S Am J Hosp Pharm; 1978 Dec; 35(12):1521-3. PubMed ID: 717407 [TBL] [Abstract][Full Text] [Related]
20. Therapeutic-interchange program for oral histamine H2-receptor antagonists. Chase SL; Peterson AM; Wordell CJ Am J Health Syst Pharm; 1998 Jul; 55(13):1382-6. PubMed ID: 9659966 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]